Search

Your search keyword '"Fujisawa, T."' showing total 163 results

Search Constraints

Start Over You searched for: Author "Fujisawa, T." Remove constraint Author: "Fujisawa, T." Publisher elsevier bv Remove constraint Publisher: elsevier bv
163 results on '"Fujisawa, T."'

Search Results

1. Genomic profiling and clinical utility of circulating tumor DNA in metastatic renal cell carcinoma: Nationwide SCRUM-Japan MONSTAR SCREEN project

3. 60MO Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN

4. 617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project

5. 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study

9. 328P Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial

14. Lack of concordance between Ki67 labeling index and 21-gene Breast Recurrence Score® test results in patients with ER+, HER2−, clinically node-negative breast cancer: a secondary analysis of TransNEOS neoadjuvant study

16. Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial

17. A multicenter phase II trial of paclitaxel, carboplatin and cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN)

18. A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)

21. Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)

23. Health-Related Quality of Life in patients with autoimmune hepatitis

27. Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis

28. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis

33. 1955 Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy

38. Identification of the origin of circulating endothelial progenitor cells

39. Treatment Outcomes and Prognostic Factors for Patients with Brain Metastases from Breast Cancer: a Multicenter Cohort Analysis

Catalog

Books, media, physical & digital resources